A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD

Trial Profile

A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Apr 2018

At a glance

  • Drugs Budesonide/formoterol (Primary) ; Formoterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms Sophos
  • Sponsors Pearl Therapeutics
  • Most Recent Events

    • 19 Apr 2018 This trial has been completed in Spain(End date: 2018-04-04).
    • 13 Apr 2018 This trial has been completed in Germany.
    • 21 Mar 2018 Planned End Date changed from 1 Aug 2018 to 30 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top